Detalles de la búsqueda
1.
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P-gp and BCRP.
Br J Clin Pharmacol
; 87(7): 2926-2936, 2021 07.
Artículo
Inglés
| MEDLINE | ID: mdl-33336408
2.
Pharmacokinetics and pharmacodynamics of CD4-anchoring bi-functional fusion inhibitor in monkeys.
Pharm Res
; 31(3): 809-18, 2014 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-24065594
3.
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers.
Clin Pharmacol Drug Dev
; 12(8): 832-838, 2023 08.
Artículo
Inglés
| MEDLINE | ID: mdl-37145975
4.
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Leuk Lymphoma
; 64(2): 329-338, 2023 02.
Artículo
Inglés
| MEDLINE | ID: mdl-36480811
5.
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Expert Rev Clin Pharmacol
; 14(11): 1329-1344, 2021 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-34491123
6.
Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
CPT Pharmacometrics Syst Pharmacol
; 10(5): 441-454, 2021 05.
Artículo
Inglés
| MEDLINE | ID: mdl-33687157
7.
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Pharmacol Res Perspect
; 9(6): e00870, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34664792
8.
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma.
Leuk Lymphoma
; 62(11): 2612-2624, 2021 11.
Artículo
Inglés
| MEDLINE | ID: mdl-34159878
9.
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Clin Transl Sci
; 14(2): 764-772, 2021 03.
Artículo
Inglés
| MEDLINE | ID: mdl-33306268
10.
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment.
Leuk Lymphoma
; 61(6): 1355-1363, 2020 06.
Artículo
Inglés
| MEDLINE | ID: mdl-32031037
11.
No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
Clin Transl Sci
; 13(5): 923-931, 2020 09.
Artículo
Inglés
| MEDLINE | ID: mdl-32144955
12.
Investigations of methylmercury-induced alterations in neurogenesis.
Environ Health Perspect
; 110 Suppl 5: 859-64, 2002 Oct.
Artículo
Inglés
| MEDLINE | ID: mdl-12426147
13.
Comparison of pharmacokinetic interactions and physiologically based pharmacokinetic modeling of PCB 153 and PCB 126 in nonpregnant mice, lactating mice, and suckling pups.
Toxicol Sci
; 65(1): 26-34, 2002 Jan.
Artículo
Inglés
| MEDLINE | ID: mdl-11752682
14.
Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay.
Toxicol Sci
; 73(2): 301-14, 2003 Jun.
Artículo
Inglés
| MEDLINE | ID: mdl-12700395
15.
Integration of biostatistics and pharmacometrics computing platforms for efficient and reproducible PK/PD analysis: a case study.
J Clin Pharmacol
; 53(11): 1112-20, 2013 Nov.
Artículo
Inglés
| MEDLINE | ID: mdl-23913679
16.
A physiologically based pharmacokinetic model for lactational transfer of PCB 153 with or without PCB 126 in mice.
Arch Toxicol
; 81(2): 101-11, 2007 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-16858609
17.
p21(WAF1/CIP1) inhibits cell cycle progression but not G2/M-phase transition following methylmercury exposure.
Toxicol Appl Pharmacol
; 178(2): 117-25, 2002 Jan 15.
Artículo
Inglés
| MEDLINE | ID: mdl-11814332
Resultados
1 -
17
de 17
1
Próxima >
>>